Rottenstein Law Group Learns of Merck Victory in Fifth Bellwether Fosamax ONJ Trial

The Rottenstein Law Group, which represents clients with claims of harm resulting from use of the drug Fosamax, has learned that Merck, manufacturer of the drug, has declared itself the victor in the fifth bellwether trial concerning the product and a condition known as osteonecrosis of the jaw. (PRWEB) October 03, 2011 On October 3, Merck issued a press release announcing that “a federal court jury in New York found in its favor in the Secrest v. Merck case, rejecting the claim of a Florida woman who blamed her dental and jaw-related problems on her FOSAMAX use.” Secrest v. Merck (case no
Contributor
About
PRWeb, a leader in online news and press release distribution, has been used by attorneys, law firms and more than 40,000 organizations